Primary and secondary anaplastic gliomas: is there a difference in the natural course of the disease?
Abstract
BACKGROUND. despite the difference in the natural course of the disease for primary and secondary glioblastomas (as well as for IDH-mutant and IDH-wild type tumors) is well known, little attention has been given to study differences in progression-free (PFS) and overall survival (OS) for primary and secondary anaplastic astrocytomas (AA) and anaplastic oligodendrogliomas (AO).
MATERIALS AND METHODS . This study was based on 79 patients with primary AA or AO and secondary aforementioned tumors, developing as a result of malignant progression of diffuse astrocytoma or oligodendroglioma, respectively. Patients from both groups were treated identically — surgery followed by adjuvant treatment.
RESULTS . Analysis of PFS and OS in these groups revealed that AAs largely followed the pattern well established for glioblastomas, meanwhile AOs demonstrated less vivid difference between primary and secondary tumors.
CONCLUSION. This is a pioneering work aiming to study differences between primary and secondary anaplastic tumors. Primary and secondary AAs demonstrated similar natural course of the disease with gliolastomas, meanwhile AOs followed it less vividly — most probably, due to the less malignant tumor behavior.
About the Authors
A. Yu. Belyaev
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
P. N. Shmakov
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
S. A. Galstyan
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
G. L. Kobiakov
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
I. N. Pronin
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
D. Yu. Usachev
Burdenko Neurosurgery Center
Russian Federation
Russian Federation
Moscow
References
1. Bhavya, B., Anand, C. R ., Madhusoodanan, U . K., Rajalakshmi, P., Krishnakumar, K., Easwer, H. v., Deepti, A. N., & Gopala, S. (2020). To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. In Cellular and Molecular Neurobiology (Vol. 40, Issue 1, pp. 53–63). Springer. https://doi.org/10.1007/s10571‑019‑00730‑3
2. M urphy, E. S., Leyrer, C. M., Parsons, M., Suh, J. H., Chao, S. T., Yu, J . S., Kotecha, R., Jia, X., Peereboom, D. M., Prayson, R. A., Stevens, G. H. J., Barnett, G. H., Vogelbaum, M. A., & Ahluwalia, M . S. (2018). Risk Factors for Malignant Transformation of Low-Grade Glioma. International Journal of Radiation Oncology*Biology*Physics, 100(4), 965–971. https://doi.org/10.1016/j.ijrobp.2017.12.258
3. Chaichana, K. L., McGirt, M. J., Laterra, J., Olivi, A., & Quiñones-Hinojosa, A. (2010). Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. Journal of Neurosurgery, 112(1), 10–17. https://doi.org/10.3171/2008.10.JNS08608
4. M cCormack, B. M., Miller, D. C., Budzilovich, G. N., Voorhees, G . J ., & Ransohoff, J. (1992). Treatment and Survival of Low-Grade Astrocytoma in Adults‑1977–1988. Neurosurgery, 31(4), 636–642. https://doi.org/10.1227/00006123‑199210000‑00004
5. van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J . M ., Kouwenhoven, M. C. M., Delattre, J. Y., Bernsen, H. J. J. A., Frenay, M ., Tijssen, C. C., Grisold, W., Sipos, L., Enting, R. H., French, P . J., Dinjens, W. N. M., Vecht, C. J., Allgeier, A., Lacombe, D ., Gorlia, T., & Hoang-Xuan, K. (2013). Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EOR TC brain tumor group study 26951. Journal of Clinical Oncology, 31(3), 344–350. https://doi.org/10.1200/JCO.2012.43.2229
6. V ertosick, F. T., Selker, R. G., & Arena, V. C. (1991). Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery, 496. https://doi.org/10.1097/00006123‑199104000‑00002
7. O hgaki, H., & Kleihues, P. (2013). The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research, 19(4), 764–772. https://doi.org/10.1158/1078–0432.CCR‑12–3002
8. P eiffer, J., & Kleihues, P. (1999). Hans-Joachim Scherer (1906–1945), pioneer in glioma research. Brain Pathology (Zurich, Switzerland), 9(2), 241–245. https://doi.org/10.1111/j.1750–3639.1999.tb00222.x
9. Scherer HJ. (1940). Cerebral astrocytomas and their derivatives. American Journal of Cancer, 40, 159–198.
10. Ohgaki, H. (2005). Genetic pathways to glioblastomas. Neuropathology, 25(1), 1–7. https://doi.org/10.1111/j.1440–1789.2004.00600.x
11. Ohgaki, H., & Kleihues, P. (2007). Genetic Pathways to Primary and Secondary Glioblastoma. The American Journal of Pathology, 170(5), 1445–1453. https://doi.org/10.2353/ajpath.2007.070011
12. Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009). IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clinical Cancer Research, 15(19), 6002–6007. https://doi.org/10.1158/1078–0432.CCR‑09–0715
13. Y an, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K. W., Velculescu, V . E ., Vogelstein, B., & Bigner, D. D. (2009). IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine, 360(8), 765–773. https://doi.org/10.1056/NEJMoa0808710
14. Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica, 116(6), 597–602. https://doi.org/10.1007/s00401‑008‑0455‑2
15. Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology, 174(4), 1149–1153. https://doi.org/10.2353/ajpath.2009.080958
16. D ropcho, E. J., & Soong, S. (1996). The prognostic impact of prior low grade histology in patients with anaplastic gliomas. Neurology, 47(3), 684–690. https://doi.org/10.1212/WNL.47.3.684
17. Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009). IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology, 11(4), 341–347. https://doi.org/10.1215/15228517‑2009‑025
18. Lai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., Ellingson, B. M ., Bowers, C. W., Soriano, R. H., Schmidt, N. O., Mohan, S., Yong, W. H., Seshagiri, S., Modrusan, Z., Jiang, Z., Phillips, H. S. (2011). Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology, 29(34), 4482–4490. https://doi.org/10.1200/JCO.2010.33.8715
19. Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020). CBTRU S Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology, 22(Supplement_1), iv1–iv96. https://doi.org/10.1093/neuonc/noaa200
20. Okamoto, Y., di Patre, P.-L., Burkhard, C., Horstmann, S., Jourde, B., Fahey, M., Schüler, D., Probst-Hensch, N. M., Yasargil, M. G., Yonekawa, Y., Lütolf, U. M., Kleihues, P., & Ohgaki, H. (2004). Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathologica, 108(1), 49–56. https://doi.org/10.1007/s00401–004–0861-z
21. G odard, S., Getz, G., Delorenzi, M., Farmer, P., Kobayashi, H., Desbaillets, I., Nozaki, M., Diserens, A.-C., Hamou, M.-F., Dietrich, P .-Y., Regli, L., Janzer, R. C., Bucher, P., Stupp, R., de Tribolet, N., Domany, E., & Hegi, M. E. (2003). Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Research, 63(20), 6613–6625.
22. Liu, S., Liu, X., Xiao, Y., Chen, S., & Zhuang, W. (2019). Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. PLO S ONE, 14(1), e0211513. https://doi.org/10.1371/journal.pone.0211513
23. Kang, H.-C., Yu, T., Lim, D. H., Kim, I. H., Chung, W.-K., Suh, C.-O., Choi, B. O ., Cho, K. H., Cho, J. H., Kim, J. H., Nam, D.-H., Park, C.-K., Hong, Y.-K., & Kim, I. A. (2015). A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13–12. Journal of Neuro-Oncology, 125(1), 207–215. https://doi.org/10.1007/s11060‑015‑1902‑2
24. Shin, D.-W., Lee, S., Song, S. W., Cho, Y. H., Hong, S. H., Kim, J. H., Kim, H. S., Park, J. E., Nam, S. J., & Kim, Y.-H. (2020). Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases. Scientific Reports, 10(1), 20162. https://doi.org/10.1038/s41598‑020‑77228‑2
25. Rogne, S. G., Konglund, A., Scheie, D., Helseth, E., & Meling, T. R. (2014). Anaplastic astrocytomas: Survival and prognostic factors in a surgical series. Acta Neurochirurgica, 156(6), 1053–1061. https://doi.org/10.1007/s00701‑014‑2053‑5
Review
For citations:
Belyaev A.Yu., Shmakov P.N., Galstyan S.A., Kobiakov G.L., Pronin I.N., Usachev D.Yu. Primary and secondary anaplastic gliomas: is there a difference in the natural course of the disease? Russian Neurosurgical Journal named after Professor A. L. Polenov. 2022;14(1-2):8-13. (In Russ.)
Views:
78
Email this article 